ID   DHX58_HUMAN             Reviewed;         678 AA.
AC   Q96C10; Q9HAM6;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   24-JUL-2024, entry version 170.
DE   RecName: Full=ATP-dependent RNA helicase DHX58 {ECO:0000305|PubMed:19211564};
DE            EC=3.6.4.13 {ECO:0000269|PubMed:19211564, ECO:0000269|PubMed:19403670};
DE   AltName: Full=ATP-dependent helicase LGP2 {ECO:0000305|PubMed:19211564};
DE   AltName: Full=Protein D11Lgp2 homolog;
DE   AltName: Full=RIG-I-like receptor 3;
DE            Short=RLR-3;
DE   AltName: Full=RIG-I-like receptor LGP2;
DE            Short=RLR;
GN   Name=DHX58 {ECO:0000312|HGNC:HGNC:29517}; Synonyms=D11LGP2E, LGP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION.
RX   PubMed=16116171; DOI=10.4049/jimmunol.175.5.2851;
RA   Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K.,
RA   Foy E., Loo Y.-M., Gale M. Jr., Akira S., Yonehara S., Kato A., Fujita T.;
RT   "Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and
RT   LGP2 in antiviral innate immunity.";
RL   J. Immunol. 175:2851-2858(2005).
RN   [4]
RP   FUNCTION, AND INTERACTION WITH MAVS AND RIGI.
RX   PubMed=17020950; DOI=10.1128/jvi.01325-06;
RA   Komuro A., Horvath C.M.;
RT   "RNA- and virus-independent inhibition of antiviral signaling by RNA
RT   helicase LGP2.";
RL   J. Virol. 80:12332-12342(2006).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH RIGI.
RX   PubMed=17190814; DOI=10.1073/pnas.0606699104;
RA   Saito T., Hirai R., Loo Y.-M., Owen D., Johnson C.L., Sinha S.C., Akira S.,
RA   Fujita T., Gale M. Jr.;
RT   "Regulation of innate antiviral defenses through a shared repressor domain
RT   in RIG-I and LGP2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:582-587(2007).
RN   [6]
RP   INTERACTION WITH ATG5 AND ATG12.
RX   PubMed=17709747; DOI=10.1073/pnas.0704014104;
RA   Jounai N., Takeshita F., Kobiyama K., Sawano A., Miyawaki A., Xin K.Q.,
RA   Ishii K.J., Kawai T., Akira S., Suzuki K., Okuda K.;
RT   "The Atg5-Atg12 conjugate associates with innate antiviral immune
RT   responses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:14050-14055(2007).
RN   [7]
RP   REVIEW ON FUNCTION.
RX   PubMed=17473309; DOI=10.1126/stke.3842007pe20;
RA   Vitour D., Meurs E.F.;
RT   "Regulation of interferon production by RIG-I and LGP2: a lesson in self-
RT   control.";
RL   Sci. STKE 2007:PE20-PE20(2007).
RN   [8]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=18411269; DOI=10.1074/jbc.m800542200;
RA   Murali A., Li X., Ranjith-Kumar C.T., Bhardwaj K., Holzenburg A., Li P.,
RA   Kao C.C.;
RT   "Structure and function of LGP2, a DEX(D/H) helicase that regulates the
RT   innate immunity response.";
RL   J. Biol. Chem. 283:15825-15833(2008).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-30; 131-ASP--HIS-134;
RP   167-THR--SER-169; 373-PHE--THR-376; 438-THR--GLU-442 AND 467-GLN--ARG-471.
RX   PubMed=19211564; DOI=10.1074/jbc.m807365200;
RA   Bamming D., Horvath C.M.;
RT   "Regulation of signal transduction by enzymatically inactive antiviral RNA
RT   helicase proteins MDA5, RIG-I, and LGP2.";
RL   J. Biol. Chem. 284:9700-9712(2009).
RN   [10]
RP   CATALYTIC ACTIVITY, AND INTERACTION WITH PARAMYXOVIRUSES NON-STRUCTURAL
RP   PROTEIN V (MICROBIAL INFECTION).
RX   PubMed=19403670; DOI=10.1128/jvi.00153-09;
RA   Parisien J.P., Bamming D., Komuro A., Ramachandran A., Rodriguez J.J.,
RA   Barber G., Wojahn R.D., Horvath C.M.;
RT   "A shared interface mediates paramyxovirus interference with antiviral RNA
RT   helicases MDA5 and LGP2.";
RL   J. Virol. 83:7252-7260(2009).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=21616437; DOI=10.1016/j.immuni.2011.05.003;
RA   Loo Y.M., Gale M. Jr.;
RT   "Immune signaling by RIG-I-like receptors.";
RL   Immunity 34:680-692(2011).
RN   [12]
RP   FUNCTION.
RX   PubMed=21187438; DOI=10.4049/jimmunol.1002862;
RA   Broquet A.H., Hirata Y., McAllister C.S., Kagnoff M.F.;
RT   "RIG-I/MDA5/MAVS are required to signal a protective IFN response in
RT   rotavirus-infected intestinal epithelium.";
RL   J. Immunol. 186:1618-1626(2011).
RN   [13]
RP   FUNCTION.
RX   PubMed=21525357; DOI=10.1128/jvi.00302-11;
RA   Chopy D., Pothlichet J., Lafage M., Megret F., Fiette L., Si-Tahar M.,
RA   Lafon M.;
RT   "Ambivalent role of the innate immune response in rabies virus
RT   pathogenesis.";
RL   J. Virol. 85:6657-6668(2011).
RN   [14]
RP   INTERACTION WITH DDX60.
RX   PubMed=21791617; DOI=10.1128/mcb.01368-10;
RA   Miyashita M., Oshiumi H., Matsumoto M., Seya T.;
RT   "DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-
RT   like receptor-mediated signaling.";
RL   Mol. Cell. Biol. 31:3802-3819(2011).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=21481967; DOI=10.1016/j.ejcb.2011.01.011;
RA   Eisenaecher K., Krug A.;
RT   "Regulation of RLR-mediated innate immune signaling--it is all about
RT   keeping the balance.";
RL   Eur. J. Cell Biol. 91:36-47(2012).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=21496944; DOI=10.1016/j.ejcb.2011.01.015;
RA   Schmidt A., Rothenfusser S., Hopfner K.P.;
RT   "Sensing of viral nucleic acids by RIG-I: from translocation to
RT   translation.";
RL   Eur. J. Cell Biol. 91:78-85(2012).
RN   [17]
RP   INTERACTION WITH ANKRD17.
RX   PubMed=23711367; DOI=10.1016/j.febslet.2013.05.037;
RA   Menning M., Kufer T.A.;
RT   "A role for the Ankyrin repeat containing protein Ankrd17 in Nod1- and
RT   Nod2-mediated inflammatory responses.";
RL   FEBS Lett. 587:2137-2142(2013).
RN   [18]
RP   FUNCTION.
RX   PubMed=33440148; DOI=10.1016/j.celrep.2020.108628;
RA   Yin X., Riva L., Pu Y., Martin-Sancho L., Kanamune J., Yamamoto Y.,
RA   Sakai K., Gotoh S., Miorin L., De Jesus P.D., Yang C.C., Herbert K.M.,
RA   Yoh S., Hultquist J.F., Garcia-Sastre A., Chanda S.K.;
RT   "MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial
RT   Cells.";
RL   Cell Rep. 34:108628-108628(2021).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 541-678 IN COMPLEX WITH RNA,
RP   FUNCTION, SUBUNIT, MUTAGENESIS OF LYS-634 AND LYS-651, AND ZINC-BINDING
RP   SITES.
RX   PubMed=19278996; DOI=10.1074/jbc.m900818200;
RA   Li X., Ranjith-Kumar C.T., Brooks M.T., Dharmaiah S., Herr A.B., Kao C.,
RA   Li P.;
RT   "The RIG-I-like receptor LGP2 recognizes the termini of double-stranded
RT   RNA.";
RL   J. Biol. Chem. 284:13881-13891(2009).
RN   [20]
RP   STRUCTURE BY NMR OF 546-678, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19380577; DOI=10.1074/jbc.m109.007179;
RA   Takahasi K., Kumeta H., Tsuduki N., Narita R., Shigemoto T., Hirai R.,
RA   Yoneyama M., Horiuchi M., Ogura K., Fujita T., Inagaki F.;
RT   "Solution structures of cytosolic RNA sensor MDA5 and LGP2 C-terminal
RT   domains: identification of the RNA recognition loop in RIG-I-like
RT   receptors.";
RL   J. Biol. Chem. 284:17465-17474(2009).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 537-678, FUNCTION, SUBUNIT,
RP   MUTAGENESIS OF LYS-634, AND ZINC-BINDING SITES.
RX   PubMed=19208642; DOI=10.1093/nar/gkp059;
RA   Pippig D.A., Hellmuth J.C., Cui S., Kirchhofer A., Lammens K., Lammens A.,
RA   Schmidt A., Rothenfusser S., Hopfner K.-P.;
RT   "The regulatory domain of the RIG-I family ATPase LGP2 senses double-
RT   stranded RNA.";
RL   Nucleic Acids Res. 37:2014-2025(2009).
RN   [22]
RP   VARIANT CYS-8, AND TISSUE SPECIFICITY.
RX   PubMed=31256877; DOI=10.1016/j.ajhg.2019.06.001;
RG   University of Washington Center for Mendelian Genomics, Baylor-Hopkins Center for Mendelian Genomics, Telethon Undiagnosed Diseases Program;
RA   Paine I., Posey J.E., Grochowski C.M., Jhangiani S.N., Rosenheck S.,
RA   Kleyner R., Marmorale T., Yoon M., Wang K., Robison R., Cappuccio G.,
RA   Pinelli M., Magli A., Coban Akdemir Z., Hui J., Yeung W.L., Wong B.K.Y.,
RA   Ortega L., Bekheirnia M.R., Bierhals T., Hempel M., Johannsen J.,
RA   Santer R., Aktas D., Alikasifoglu M., Bozdogan S., Aydin H., Karaca E.,
RA   Bayram Y., Ityel H., Dorschner M., White J.J., Wilichowski E.,
RA   Wortmann S.B., Casella E.B., Kitajima J.P., Kok F., Monteiro F.,
RA   Muzny D.M., Bamshad M., Gibbs R.A., Sutton V.R., Van Esch H.,
RA   Brunetti-Pierri N., Hildebrandt F., Brautbar A., Van den Veyver I.B.,
RA   Glass I., Lessel D., Lyon G.J., Lupski J.R.;
RT   "Paralog studies augment gene discovery: DDX and DHX genes.";
RL   Am. J. Hum. Genet. 105:302-316(2019).
CC   -!- FUNCTION: Acts as a regulator of RIGI and IFIH1/MDA5 mediated antiviral
CC       signaling. Cannot initiate antiviral signaling as it lacks the CARD
CC       domain required for activating MAVS/IPS1-dependent signaling events.
CC       Can have both negative and positive regulatory functions related to
CC       RIGI and IFIH1/MDA5 signaling and this role in regulating signaling may
CC       be complex and could probably depend on characteristics of the
CC       infecting virus or target cells, or both. Its inhibitory action on RIG-
CC       I signaling may involve the following mechanisms: competition with RIGI
CC       for binding to the viral RNA, binding to RIGI and inhibiting its
CC       dimerization and interaction with MAVS/IPS1, competing with IKBKE in
CC       its binding to MAVS/IPS1 thereby inhibiting activation of interferon
CC       regulatory factor 3 (IRF3). Its positive regulatory role may involve
CC       unwinding or stripping nucleoproteins of viral RNA thereby facilitating
CC       their recognition by RIGI and IFIH1/MDA5. Involved in the innate immune
CC       response to various RNA viruses and some DNA viruses such as poxviruses
CC       and coronavirus SARS-CoV-2, and also to the bacterial pathogen Listeria
CC       monocytogenes (PubMed:31256877). Can bind both ssRNA and dsRNA, with a
CC       higher affinity for dsRNA. Shows a preference to 5'-triphosphorylated
CC       RNA, although it can recognize RNA lacking a 5'-triphosphate.
CC       {ECO:0000269|PubMed:16116171, ECO:0000269|PubMed:17020950,
CC       ECO:0000269|PubMed:17190814, ECO:0000269|PubMed:18411269,
CC       ECO:0000269|PubMed:19208642, ECO:0000269|PubMed:19211564,
CC       ECO:0000269|PubMed:19278996, ECO:0000269|PubMed:19380577,
CC       ECO:0000269|PubMed:21187438, ECO:0000269|PubMed:21525357,
CC       ECO:0000269|PubMed:31256877}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC         Evidence={ECO:0000269|PubMed:19211564, ECO:0000269|PubMed:19403670};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000305|PubMed:19211564};
CC   -!- SUBUNIT: Monomer in the absence of dsRNA. Homodimer in the presence of
CC       dsRNA. Interacts with RIGI (via CARD domain), MAVS/IPS1 and DDX60.
CC       Found in a complex with RIGI and IFIH1/MDA5. Interacts with ANKRD17.
CC       Directly interacts with ATG5 and ATG12, either as ATG5 and ATG12
CC       monomers or as ATG12-ATG5 conjugates (PubMed:17709747).
CC       {ECO:0000269|PubMed:17020950, ECO:0000269|PubMed:17190814,
CC       ECO:0000269|PubMed:17709747, ECO:0000269|PubMed:18411269,
CC       ECO:0000269|PubMed:19208642, ECO:0000269|PubMed:19278996,
CC       ECO:0000269|PubMed:21791617, ECO:0000269|PubMed:23711367}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via helicase C-terminal
CC       domain) with non-structural protein V of paramyxoviruses including
CC       human parainfluenza 2 virus, human parainfluenza 5 virus, measles
CC       virus, mumps virus, hendra virus and nipah virus.
CC       {ECO:0000269|PubMed:19403670}.
CC   -!- INTERACTION:
CC       Q96C10; Q9UKV8: AGO2; NbExp=2; IntAct=EBI-744193, EBI-528269;
CC       Q96C10; Q7L2E3: DHX30; NbExp=2; IntAct=EBI-744193, EBI-1211456;
CC       Q96C10; Q9UPY3: DICER1; NbExp=2; IntAct=EBI-744193, EBI-395506;
CC       Q96C10; P19525: EIF2AK2; NbExp=2; IntAct=EBI-744193, EBI-640775;
CC       Q96C10; P56537: EIF6; NbExp=2; IntAct=EBI-744193, EBI-372243;
CC       Q96C10; Q16666: IFI16; NbExp=2; IntAct=EBI-744193, EBI-2867186;
CC       Q96C10; O15226: NKRF; NbExp=2; IntAct=EBI-744193, EBI-766011;
CC       Q96C10; Q9NUL3: STAU2; NbExp=2; IntAct=EBI-744193, EBI-722938;
CC       Q96C10; P11207: P/V; Xeno; NbExp=2; IntAct=EBI-744193, EBI-6148694;
CC       Q96C10; P30927: P/V; Xeno; NbExp=2; IntAct=EBI-744193, EBI-6599165;
CC       Q96C10; Q9EMA9: P/V; Xeno; NbExp=2; IntAct=EBI-744193, EBI-6598728;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19380577}.
CC   -!- TISSUE SPECIFICITY: Expressed in testis, nerve and spleen. Also
CC       expressed in the brain. {ECO:0000269|PubMed:31256877}.
CC   -!- INDUCTION: By interferon (IFN), virus infection, or intracellular
CC       dsRNA.
CC   -!- DOMAIN: The RLR CTR domain is capable of inhibiting dimerization and
CC       signaling of RIGI and also facilitates binding of dsRNA.
CC   -!- SIMILARITY: Belongs to the helicase family. RLR subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK021416; BAB13818.1; -; mRNA.
DR   EMBL; BC014949; AAH14949.1; -; mRNA.
DR   CCDS; CCDS11416.1; -.
DR   RefSeq; NP_077024.2; NM_024119.2.
DR   RefSeq; XP_016880548.1; XM_017025059.1.
DR   RefSeq; XP_016880549.1; XM_017025060.1.
DR   PDB; 2RQA; NMR; -; A=546-678.
DR   PDB; 2W4R; X-ray; 2.60 A; A/B/C/D=537-678.
DR   PDB; 3EQT; X-ray; 2.00 A; A/B=541-678.
DR   PDBsum; 2RQA; -.
DR   PDBsum; 2W4R; -.
DR   PDBsum; 3EQT; -.
DR   AlphaFoldDB; Q96C10; -.
DR   SMR; Q96C10; -.
DR   BioGRID; 122553; 24.
DR   DIP; DIP-60792N; -.
DR   IntAct; Q96C10; 21.
DR   STRING; 9606.ENSP00000251642; -.
DR   iPTMnet; Q96C10; -.
DR   PhosphoSitePlus; Q96C10; -.
DR   SwissPalm; Q96C10; -.
DR   BioMuta; DHX58; -.
DR   DMDM; 50401123; -.
DR   MassIVE; Q96C10; -.
DR   PaxDb; 9606-ENSP00000251642; -.
DR   PeptideAtlas; Q96C10; -.
DR   ProteomicsDB; 76141; -.
DR   TopDownProteomics; Q96C10; -.
DR   Antibodypedia; 16840; 390 antibodies from 36 providers.
DR   DNASU; 79132; -.
DR   Ensembl; ENST00000251642.8; ENSP00000251642.3; ENSG00000108771.13.
DR   GeneID; 79132; -.
DR   KEGG; hsa:79132; -.
DR   MANE-Select; ENST00000251642.8; ENSP00000251642.3; NM_024119.3; NP_077024.2.
DR   UCSC; uc002hyw.5; human.
DR   AGR; HGNC:29517; -.
DR   CTD; 79132; -.
DR   DisGeNET; 79132; -.
DR   GeneCards; DHX58; -.
DR   HGNC; HGNC:29517; DHX58.
DR   HPA; ENSG00000108771; Low tissue specificity.
DR   MIM; 608588; gene.
DR   neXtProt; NX_Q96C10; -.
DR   OpenTargets; ENSG00000108771; -.
DR   PharmGKB; PA162383566; -.
DR   VEuPathDB; HostDB:ENSG00000108771; -.
DR   eggNOG; KOG0354; Eukaryota.
DR   GeneTree; ENSGT00940000153173; -.
DR   HOGENOM; CLU_006888_2_1_1; -.
DR   InParanoid; Q96C10; -.
DR   OMA; HRAVGNY; -.
DR   OrthoDB; 342391at2759; -.
DR   PhylomeDB; Q96C10; -.
DR   TreeFam; TF330258; -.
DR   PathwayCommons; Q96C10; -.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   SignaLink; Q96C10; -.
DR   BioGRID-ORCS; 79132; 12 hits in 1148 CRISPR screens.
DR   ChiTaRS; DHX58; human.
DR   EvolutionaryTrace; Q96C10; -.
DR   GeneWiki; LGP2; -.
DR   GenomeRNAi; 79132; -.
DR   Pharos; Q96C10; Tbio.
DR   PRO; PR:Q96C10; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q96C10; Protein.
DR   Bgee; ENSG00000108771; Expressed in granulocyte and 99 other cell types or tissues.
DR   ExpressionAtlas; Q96C10; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IMP:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:InterPro.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0003724; F:RNA helicase activity; IMP:UniProtKB.
DR   GO; GO:0003727; F:single-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0140374; P:antiviral innate immune response; IBA:GO_Central.
DR   GO; GO:0002753; P:cytoplasmic pattern recognition receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045824; P:negative regulation of innate immune response; IDA:UniProtKB.
DR   GO; GO:0039534; P:negative regulation of MDA-5 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0039536; P:negative regulation of RIG-I signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; IDA:UniProtKB.
DR   GO; GO:1900245; P:positive regulation of MDA-5 signaling pathway; ISS:UniProtKB.
DR   GO; GO:1900246; P:positive regulation of RIG-I signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; ISS:UniProtKB.
DR   GO; GO:0045088; P:regulation of innate immune response; IDA:UniProtKB.
DR   GO; GO:0009617; P:response to bacterium; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; ISS:UniProtKB.
DR   CDD; cd18075; DEXHc_RLR-3; 1.
DR   CDD; cd15806; LGP2_C; 1.
DR   CDD; cd12090; MDA5_ID; 1.
DR   CDD; cd18802; SF2_C_dicer; 1.
DR   Gene3D; 1.20.1320.30; -; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   Gene3D; 2.170.150.30; RIG-I-like receptor, C-terminal regulatory domain; 1.
DR   InterPro; IPR006935; Helicase/UvrB_N.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR041204; RIG-I-like_C.
DR   InterPro; IPR038557; RLR_C_sf.
DR   InterPro; IPR021673; RLR_CTR.
DR   InterPro; IPR051363; RLR_Helicase.
DR   PANTHER; PTHR14074:SF7; ATP-DEPENDENT RNA HELICASE DHX58; 1.
DR   PANTHER; PTHR14074; HELICASE WITH DEATH DOMAIN-RELATED; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF04851; ResIII; 1.
DR   Pfam; PF18119; RIG-I_C; 1.
DR   Pfam; PF11648; RIG-I_C-RD; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS51789; RLR_CTR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antiviral defense; ATP-binding; Coiled coil; Cytoplasm;
KW   Helicase; Host-virus interaction; Hydrolase; Immunity; Innate immunity;
KW   Metal-binding; Nucleotide-binding; Reference proteome; RNA-binding; Zinc.
FT   CHAIN           1..678
FT                   /note="ATP-dependent RNA helicase DHX58"
FT                   /id="PRO_0000102010"
FT   DOMAIN          11..188
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          350..514
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   DOMAIN          539..669
FT                   /note="RLR CTR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01125"
FT   REGION          572..655
FT                   /note="RNA-binding"
FT   COILED          489..546
FT                   /evidence="ECO:0000255"
FT   MOTIF           131..134
FT                   /note="DECH box"
FT   BINDING         24..31
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   BINDING         556
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01125"
FT   BINDING         559
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01125"
FT   BINDING         612
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01125"
FT   BINDING         615
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01125"
FT   VARIANT         8
FT                   /note="W -> C (found in a patient with a neurodevelopmental
FT                   disorder; uncertain significance; dbSNP:rs200502586)"
FT                   /evidence="ECO:0000269|PubMed:31256877"
FT                   /id="VAR_083645"
FT   VARIANT         76
FT                   /note="T -> A (in dbSNP:rs34891485)"
FT                   /id="VAR_049336"
FT   VARIANT         95
FT                   /note="R -> Q (in dbSNP:rs35118457)"
FT                   /id="VAR_049337"
FT   VARIANT         425
FT                   /note="Q -> R (in dbSNP:rs2074158)"
FT                   /id="VAR_019394"
FT   VARIANT         523
FT                   /note="R -> Q (in dbSNP:rs2074160)"
FT                   /id="VAR_019395"
FT   MUTAGEN         30
FT                   /note="K->A: Loss of dsRNA-induced ATPase activity. No
FT                   effect on ds-RNA binding. No effect on cytoplasmic pattern
FT                   recognition receptor signaling pathway in response to
FT                   virus."
FT                   /evidence="ECO:0000269|PubMed:19211564"
FT   MUTAGEN         131..134
FT                   /note="DECH->AACA: Loss of dsRNA-induced ATPase activity."
FT                   /evidence="ECO:0000269|PubMed:19211564"
FT   MUTAGEN         167..169
FT                   /note="TAS->AAA: Loss of dsRNA-induced ATPase activity.
FT                   Loss of ds-RNA binding. No effect on cytoplasmic pattern
FT                   recognition receptor signaling pathway in response to
FT                   virus."
FT                   /evidence="ECO:0000269|PubMed:19211564"
FT   MUTAGEN         373..376
FT                   /note="FTRT->ATRA: Loss of dsRNA-induced ATPase activity.
FT                   No effect on cytoplasmic pattern recognition receptor
FT                   signaling pathway in response to virus."
FT                   /evidence="ECO:0000269|PubMed:19211564"
FT   MUTAGEN         438..442
FT                   /note="TSVAE->ASVAA: Loss of dsRNA-induced ATPase activity.
FT                   No effect on cytoplasmic pattern recognition receptor
FT                   signaling pathway in response to virus."
FT                   /evidence="ECO:0000269|PubMed:19211564"
FT   MUTAGEN         467..471
FT                   /note="QARGR->AARGA: Loss of dsRNA-induced ATPase activity.
FT                   No effect on cytoplasmic pattern recognition receptor
FT                   signaling pathway in response to virus."
FT                   /evidence="ECO:0000269|PubMed:19211564"
FT   MUTAGEN         634
FT                   /note="K->E: Abolishes RNA binding."
FT                   /evidence="ECO:0000269|PubMed:19208642,
FT                   ECO:0000269|PubMed:19278996"
FT   MUTAGEN         651
FT                   /note="K->E: Abolishes RNA binding."
FT                   /evidence="ECO:0000269|PubMed:19278996"
FT   CONFLICT        473
FT                   /note="R -> W (in Ref. 1; BAB13818)"
FT                   /evidence="ECO:0000305"
FT   HELIX           549..551
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          553..556
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   TURN            557..559
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          562..565
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   HELIX           566..568
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          569..572
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   TURN            573..575
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          576..579
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   HELIX           582..587
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          588..590
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          592..594
FT                   /evidence="ECO:0007829|PDB:2RQA"
FT   STRAND          597..599
FT                   /evidence="ECO:0007829|PDB:2RQA"
FT   STRAND          602..612
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   TURN            613..615
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          618..625
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          628..633
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   HELIX           635..637
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          638..642
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          645..647
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   HELIX           652..654
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   STRAND          655..657
FT                   /evidence="ECO:0007829|PDB:2W4R"
FT   HELIX           664..671
FT                   /evidence="ECO:0007829|PDB:3EQT"
FT   HELIX           675..677
FT                   /evidence="ECO:0007829|PDB:3EQT"
SQ   SEQUENCE   678 AA;  76613 MW;  859E1749C7313D06 CRC64;
     MELRSYQWEV IMPALEGKNI IIWLPTGAGK TRAAAYVAKR HLETVDGAKV VVLVNRVHLV
     TQHGEEFRRM LDGRWTVTTL SGDMGPRAGF GHLARCHDLL ICTAELLQMA LTSPEEEEHV
     ELTVFSLIVV DECHHTHKDT VYNVIMSQYL ELKLQRAQPL PQVLGLTASP GTGGASKLDG
     AINHVLQLCA NLDTWCIMSP QNCCPQLQEH SQQPCKQYNL CHRRSQDPFG DLLKKLMDQI
     HDHLEMPELS RKFGTQMYEQ QVVKLSEAAA LAGLQEQRVY ALHLRRYNDA LLIHDTVRAV
     DALAALQDFY HREHVTKTQI LCAERRLLAL FDDRKNELAH LATHGPENPK LEMLEKILQR
     QFSSSNSPRG IIFTRTRQSA HSLLLWLQQQ QGLQTVDIRA QLLIGAGNSS QSTHMTQRDQ
     QEVIQKFQDG TLNLLVATSV AEEGLDIPHC NVVVRYGLLT NEISMVQARG RARADQSVYA
     FVATEGSREL KRELINEALE TLMEQAVAAV QKMDQAEYQA KIRDLQQAAL TKRAAQAAQR
     ENQRQQFPVE HVQLLCINCM VAVGHGSDLR KVEGTHHVNV NPNFSNYYNV SRDPVVINKV
     FKDWKPGGVI SCRNCGEVWG LQMIYKSVKL PVLKVRSMLL ETPQGRIQAK KWSRVPFSVP
     DFDFLQHCAE NLSDLSLD
//